556 related articles for article (PubMed ID: 26248256)
1. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
2. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
3. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
11. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Lee J; Kefford R; Carlino M
Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death-1 inhibition in lymphoma.
Hawkes EA; Grigg A; Chong G
Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
18. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
19. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
